Ignite Creation Date:
2024-05-06 @ 4:10 PM
Last Modification Date:
2024-10-26 @ 2:05 PM
Study NCT ID:
NCT04897126
Status:
COMPLETED
Last Update Posted:
2024-04-23
First Post:
2021-05-19
Brief Title:
Efficacy and Safety of Shexiang Baoxin Pill in Patients With Ischemia With Non-Obstructive Coronary Artery
Sponsor:
Shanghai Hutchison Pharmaceuticals Limited
Organization:
Shanghai Hutchison Pharmaceuticals Limited
Study Overview
Official Title:
Efficacy and Safety of Shexiang Baoxin Pill in Patients With Ischemia With Non-Obstructive Coronary Artery A Phase 4 Multicenter Randomized Double-blind Placebo-controlled Clinical Trial
Status:
COMPLETED
Status Verified Date:
2024-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
LESS
Brief Summary:
This is a multicenter randomized double-blind placebo-controlled clinical trial Patients were treated with the trial drug or placebo in a 11 ratio The control group was treated with placebo 4 pills day 3 times day on the basis of conventional treatment until the end of follow-up while the experimental group was treated with MUSK Pill 4 pills day 3 times day on the basis of conventional treatment until the end of follow-up
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None